Abstracts tagged "treatment and tyrosine kinase inhibition"

Abstract Number: 850 • ACR/ARHP Annual Meeting 2014
Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib
Jacqueline E. Paramarta¹, Maureen C. Turina¹, Tanja F. Heijda², Iris C. Blijdorp³, Troy Noordenbos¹, Nataliya Yeremenko² and Dominique L. Baeten⁴, ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Immunopathological studies on synovitis recently identified the mast cell as potential novel therapeutic target in spondyloarthritis (SpA).[1] Mast cells can be targeted by inhibiting…
Abstract Number: 2566 • ACR/ARHP Annual Meeting 2013
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Tammara A. Wood², Robert F. Spiera¹ and Michael L. Whitfield², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…
Abstract Number: 709 • ACR/ARHP Annual Meeting 2013
Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Jessica K. Gordon¹, Cynthia Magro², Uzunma Udeh¹, Daniele Lerner¹, Horatio F. Wildman³, Wei-Ti Huang⁴, Mary K. Crow⁵ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Dermatopathology, Weill-Cornell Medical Center, New York, NY, ³Dermatology, Weill-Cornell Medical Center, New York, NY, ⁴Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.) Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…